Abstract: This report describes the results of two different, multi-laboratory QC studies that were used 12 to establish QC ranges for the novel gyrase inhibitor, zoliflodacin, against the ATCC strains 13 recommended by the Clinical and Laboratory Standards Institute (CLSI). Following the completion of an 14 eight-laboratory, CLSI document M23-defined tier 2 study, the agar dilution MIC quality control (QC) 15 range for zoliflodacin against the Neisseria gonorrhoeae QC strain ATCC 49226 was defined as 0.06 -0.5 16 µg/mL and was approved by the CLSI Subcommittee on Antimicrobial Susceptibility Testing. This QC 17 range will be used for in vitro susceptibility testing of zoliflodacin during phase 3 human clinical trials 18 and surveillance studies, and eventually will be implemented in clinical labs. In a separate study, broth 19 microdilution MIC quality control ranges for zoliflodacin against the following additional QC strains were 20 determined to be: 0.12 -0.5 µg/mL for Staphylococcus aureus ATCC 29213, 0.25 -2 µg/mL for 21
2
The US Centers for Disease Control and Prevention (CDC) has designated N. gonorrhoeae as an urgent 31 public health threat that requires aggressive action due to emerging antibiotic resistance. In 2013, the 32 CDC estimated an incidence of approximately 820,000 cases of gonorrhea in the United States alone, of 33 which ~30% were resistant to existing antibiotics (1). Zoliflodacin (previously known as ETX0914 or 34 AZD0914) is a novel, orally bioavailable spiropyrimidinetrione inhibitor of bacterial DNA gyrase (2) 35 ( Figure 1 ) currently in clinical development for the treatment of uncomplicated gonorrhea. Due to its 36 unique mechanism of action, zoliflodacin is not cross-resistant to any other antibacterial agents, 37 including other classes of gyrase inhibitors such as the fluoroquinolones, aminocoumarins or NBTIs (2). 38
The compound, which has been granted qualified infectious disease product (QIDP) status and fast track 39 designation by the U.S. Food and Drug Administration, has successfully completed both Phase I (3) and 40
Phase 2 (4) clinical studies and will initiate Phase 3 testing in 2019. Zoliflodacin is rapidly bactericidal 41 against clinical isolates of N. gonorrhoeae with low frequencies of resistance emergence (5). In recent 42 surveillance studies, zoliflodacin was found to have potent antibacterial activity against contemporary 43 clinical isolates from around the world (6, 7). 44
To ensure test performance and accuracy of results, a validated quality control (QC) method needs to be 45 included in every study that involves in vitro susceptibility testing. QC methods rely on limits of 46 variability which are established when testing an antibiotic against relevant QC strains and which are set 47 according to the Clinical and Laboratory Standards Institute (CLSI) document M23 tier 2 studies. These 48 include the evaluation of the reproducibility of antimicrobial susceptibility testing methods using 49 different lots of reagents within a laboratory as well as among different laboratories over multiple days 50 of testing and multiple replicates (8). The QC ranges established in this way are reported in applicable 51 standard documents such as CLSI M100 (9). 52
In this report, we describe the results of two different, multi-laboratory QC studies that were used to 53 establish QC ranges for zoliflodacin against the ATCC strains recommended by CLSI. The results of the 54 agar dilution and broth microdilution MIC studies were approved at the June 2014 and January 2015 55 meetings, respectively, of the CLSI subcommittee on Antimicrobial Susceptibility Testing 56 (https://clsi.org/meetings/ast-file-resources/) and will be used during Phase 3 clinical testing as well as 57 future surveillance studies and eventually laboratories conducting testing on patient isolates. Table 1 and Figure 2 . Based on guidance from the CLSI M23 document, 63 the 57% MIC shoulder present at 0.25 µg/mL indicated the need for a four-dilution quality control range 64 (8). Therefore, 0.06 -0.5 µg/mL was recommended for quality control testing, which was confirmed by 65 the RangeFinder method analysis (10). This range included 100% of all reported results. Significant lot-66 to-lot variability in base media was not observed with any of the three agar lots tested. All agar MIC 67 results for ceftriaxone, the control agent, were within the CLSI-approved range on each day of testing 68 (data not shown). 69
Because zoliflodacin has antibacterial activity against other bacterial species in addition to N. Figure 3E ) demonstrated large MIC shoulders of 94.3% and 78 82.7%, respectively, suggesting bimodal distributions of the data divided between two 2-fold dilutions. 79 Therefore, four-dilution QC ranges were recommended for both E. faecalis ATCC 29212 and H. 80 influenzae ATCC 49247. Zoliflodacin modal MICs for all lots of media were within the proposed dilution 81 ranges. All values for the control antibiotic, levofloxacin, were within CLSI-approved ranges except for 82 three replicates for H. influenzae ATCC 49247 (data not shown). Removing the data associated with 83 these three "out of control" replicates did not change the MIC range proposed for zoliflodacin. 84
Discussion 85
Establishing QC ranges for antibiotic susceptibility testing is an absolute necessity to ensure accurate 86 and reproducible reporting of results. This is accomplished by the testing of well-established QC strains 87 with known susceptibilities to the antimicrobial agent of interest (8). The goals of a QC program are to 88 monitor the precision (reproducibility) and accuracy of susceptibility testing procedures, the 89 performance of reagents used in routine tests, and the performance of laboratory personnel who 90 on August 7, 2019 at UNIV OF CALIF SAN DIEGO http://jcm.asm.org/ Downloaded from execute the tests and report the results (8). The studies described here met CLSI document M23 91 requirements for tier 2 QC studies to establish MIC ranges for this novel antibacterial agent. 92 Table 7 summarizes the approved QC ranges for zoliflodacin MIC tests for the six organisms evaluated in 93 these studies. Due to growth requirements, N. gonorrhoeae MIC tests had to be conducted using agar 94 dilution methods in appropriate media (11). MIC tests for the remaining five bacterial species were 95 conducted using the broth microdilution method (11). All (100%) of MIC values reported from the eight 96 participating laboratories in this study were within the QC ranges shown in Table 7 . The results from 97 this multi-laboratory QC study for zoliflodacin were approved by the CLSI antimicrobial susceptibility 98 testing subcommittee for future publication in document M100 (9). 99 
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Proposed QC ranges for zoliflodacin for all ATCC strains for both broth and agar dilution testing were 150 generated using document M23 criteria (8) 
